Jasper Therapeutics (NASDAQ:JSPR) Trading Down 5% – Here’s What Happened

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was down 5% during trading on Monday . The stock traded as low as $0.4551 and last traded at $0.4680. Approximately 569,497 shares changed hands during mid-day trading, a decline of 6% from the average daily volume of 603,662 shares. The stock had previously closed at $0.4927.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. TD Cowen cut Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. UBS Group assumed coverage on shares of Jasper Therapeutics in a report on Monday, March 23rd. They issued a “neutral” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Tuesday, April 21st. Finally, Royal Bank Of Canada set a $3.00 price objective on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a report on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $13.14.

Jasper Therapeutics Stock Down 0.4%

The company’s 50-day moving average is $0.83 and its 200-day moving average is $1.28. The stock has a market cap of $13.00 million, a price-to-earnings ratio of -0.14 and a beta of 3.00.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.08. On average, research analysts forecast that Jasper Therapeutics, Inc. will post -1.81 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its holdings in Jasper Therapeutics by 6,394.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,746,492 shares of the company’s stock valued at $3,196,000 after purchasing an additional 1,719,602 shares during the last quarter. Acorn Capital Advisors LLC acquired a new stake in shares of Jasper Therapeutics during the third quarter worth approximately $3,291,000. Velan Capital Investment Management LP increased its holdings in shares of Jasper Therapeutics by 86.1% during the third quarter. Velan Capital Investment Management LP now owns 2,668,395 shares of the company’s stock worth $6,206,000 after buying an additional 1,234,567 shares in the last quarter. Woodline Partners LP bought a new position in shares of Jasper Therapeutics in the third quarter valued at approximately $2,475,000. Finally, Propel Bio Management LLC acquired a new position in shares of Jasper Therapeutics in the 3rd quarter worth approximately $2,449,000. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.